Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer

Nat Commun. 2022 Aug 30;13(1):5095. doi: 10.1038/s41467-022-32816-w.

Abstract

The tumor immune microenvironment (TIME) is associated with tumor prognosis and immunotherapy response. Here we develop and validate a CT-based radiomics score (RS) using 2272 gastric cancer (GC) patients to investigate the relationship between the radiomics imaging biomarker and the neutrophil-to-lymphocyte ratio (NLR) in the TIME, including its correlation with prognosis and immunotherapy response in advanced GC. The RS achieves an AUC of 0.795-0.861 in predicting the NLR in the TIME. Notably, the radiomics imaging biomarker is indistinguishable from the IHC-derived NLR status in predicting DFS and OS in each cohort (HR range: 1.694-3.394, P < 0.001). We find the objective responses of a cohort of anti-PD-1 immunotherapy patients is significantly higher in the low-RS group (60.9% and 42.9%) than in the high-RS group (8.1% and 14.3%). The radiomics imaging biomarker is a noninvasive method to evaluate TIME, and may correlate with prognosis and anti PD-1 immunotherapy response in GC patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Humans
  • Immunotherapy
  • Lymphocytes / pathology
  • Neutrophils / pathology
  • Stomach Neoplasms* / diagnostic imaging
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy
  • Tumor Microenvironment

Substances

  • Biomarkers